196 related articles for article (PubMed ID: 35965534)
1. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
Sabatier R; Garnier S; Guille A; Carbuccia N; Pakradouni J; Adelaide J; Provansal M; Cappiello M; Rousseau F; Chaffanet M; Birnbaum D; Mamessier E; Gonçalves A; Bertucci F
Front Oncol; 2022; 12():946257. PubMed ID: 35965534
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.
Nguyen MTN; Rajavuori A; Huhtinen K; Hietanen S; Hynninen J; Oikkonen J; Hautaniemi S
Biomed Pharmacother; 2023 Dec; 168():115630. PubMed ID: 37806091
[TBL] [Abstract][Full Text] [Related]
3. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing.
Kang M; Cho E; Jang J; Lee J; Jeon Y; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Investig Clin Urol; 2019 Jul; 60(4):227-234. PubMed ID: 31294131
[TBL] [Abstract][Full Text] [Related]
5. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
6. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
Kim MH; Kim GM; Ahn JM; Ryu WJ; Kim SG; Kim JH; Kim TY; Han HJ; Kim JY; Park HS; Park S; Park BW; Kim SI; Jeong J; Lee J; Paik S; Kim S; Jung KH; Cho EH; Sohn J
J Natl Cancer Inst; 2023 Sep; 115(9):1036-1049. PubMed ID: 37166557
[TBL] [Abstract][Full Text] [Related]
7. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
Eur Urol; 2024 May; ():. PubMed ID: 38811314
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
10. Assessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma.
Duan H; Hu JL; Chen ZH; Li JH; He ZQ; Wang ZN; Zhang GH; Guo XY; Liang L; Mou YG
Chin Med J (Engl); 2020 Jun; 133(12):1415-1421. PubMed ID: 32558704
[TBL] [Abstract][Full Text] [Related]
11. Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice.
Imperial R; Nazer M; Ahmed Z; Kam AE; Pluard TJ; Bahaj W; Levy M; Kuzel TM; Hayden DM; Pappas SG; Subramanian J; Masood A
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546879
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Noguchi T; Iwahashi N; Sakai K; Matsuda K; Matsukawa H; Toujima S; Nishio K; Ino K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207545
[TBL] [Abstract][Full Text] [Related]
13. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease.
Hemming ML; Klega KS; Rhoades J; Ha G; Acker KE; Andersen JL; Thai E; Nag A; Thorner AR; Raut CP; George S; Crompton BD
JCO Precis Oncol; 2019; 2019():. PubMed ID: 30793095
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
15. Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma.
Wang X; Li X; Cheng Y; Sun X; Sun X; Self S; Kooperberg C; Dai JY
Hum Genomics; 2015 Sep; 9(1):22. PubMed ID: 26374103
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma.
Diefenbach RJ; Lee JH; Strbenac D; Yang JYH; Menzies AM; Carlino MS; Long GV; Spillane AJ; Stretch JR; Saw RPM; Thompson JF; Ch'ng S; Scolyer RA; Kefford RF; Rizos H
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795494
[TBL] [Abstract][Full Text] [Related]
17. The dynamic range of circulating tumor DNA in metastatic breast cancer.
Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
Sabatier R; Vicier C; Garnier S; Guille A; Carbuccia N; Isambert N; Dalenc F; Robert M; Levy C; Pakradouni J; Adelaïde J; Chaffanet M; Sfumato P; Mamessier E; Bertucci F; Goncalves A
Mol Oncol; 2022 May; 16(10):2057-2070. PubMed ID: 35122700
[TBL] [Abstract][Full Text] [Related]
19. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
20. Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.
Marchi G; Rajavuori A; Nguyen MTN; Huhtinen K; Oksa S; Hietanen S; Hautaniemi S; Hynninen J; Oikkonen J
Transl Oncol; 2024 Jan; 39():101814. PubMed ID: 37924564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]